Two of INC’s largest shareholders to dump majority of ownership

Two major owners of INC Research ($INCR) have announced that they are to sell off 4.5 million shares as they look to lower their financial interest in the CRO.

Avista Capital Partners and affiliates of Ontario Teachers’ Pension Plan (OTPP) are the two companies in question, with INC saying in a statement that it intends to buy around 1.5 million of these shares back in a stock repurchase program.

The sell-off will see Avista own just under 4% of the CRO, while OTPP will own exactly zero. The two just a year ago owned collectively around two-thirds of the company.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

This comes as rumors persist that the highly acquisitive LabCorp ($LH) is seeking to buy INC, although no move has yet been made public.

INC saw its net service revenue for Q1 jump 17.7% to $249 million, when compared to last year, with this growth primarily driven by a particularly strong showing in the central nervous system, oncology and other complex therapeutic areas.

But alongside these figures the CRO also announced that it was to cull around 175 staffers, including 30 from its Raleigh HQ. In the second quarter, INC recorded $259 million of net service revenue, a 14 % rise.

The company saw its shares fall by 3% at the end of play yesterday on the news.

- check out the release

Related Articles:
LabCorp target INC Research posts strong Q1, 175 posts axed
INC Research joins clinical trial awareness push

Read more on

Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.